There has been growing interest in the potential anticancer activity of statins based on preclinical evidence of their antiproliferative, proapoptotic, and radiosensitizing properties. The primary objective of this study was to determine whether statin use is associated with improved clinical outcomes in patients treated with radiotherapy (RT) for prostate cancer.
INTRODUCTION
The management of prostate cancer is a significant health care challenge. Many treatment options exist, [1] [2] [3] but the morbidity and cost of treatment are not trivial. 4, 5 Although risk classification schemes 6 and nomograms 7 attempt to identify men most likely to benefit from treatment, it remains difficult to balance the risks of disease progression against competing risks of mortality. 8 This has resulted in controversy over prostate-specific antigen (PSA) screening 9, 10 and possible overtreatment leading to decreased quality of life 5, 11 and a drain on health care dollars. 12, 13 It is therefore of interest to conduct research regarding cancer prevention, 14 identification
of men who will benefit most from treatment, and effective therapy that limits treatment-related morbidity at reasonable cost. Statins are cholesterol-lowering medications in widespread use to reduce the risk of heart disease and all-cause mortality. [15] [16] [17] Statins have been shown to prevent cell proliferation of various cell types, including endothelial cells, 18 and to improve cardiovascular health. 17, 19 There is growing interest in the anticancer activity of these medications. [20] [21] [22] [23] Several investigators 20, [23] [24] [25] have noted that statin users may have lower cancer risk than nonusers. In particular, large studies 20, 26 have shown a reduced risk of advanced prostate cancer in statin users. Statin use has also been associated with improved
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2 8 ⅐ N U M B E Routcomes in patients undergoing radiation therapy (RT) and/or chemotherapy for rectal cancer, 27 hepatocellular carcinoma, 28 and bladder cancer. 29 We sought to determine the impact of statin therapy on clinical outcomes in a cohort of men treated with curative-intent RT for prostate cancer. A favorable interaction between statin use and RT on clinical outcome could have implications toward creating a low-cost, low-morbidity treatment option for men with prostate cancer. In this study, we compared the rates of biochemical control and relapse-free survival (RFS) for men undergoing RT for prostate cancer who were using a statin against the rates for men not using a statin. In addition, we sought to determine whether statin dosage, pretreatment cholesterol levels, and low-density lipoprotein (LDL) levels were associated with the magnitude of effect.
PATIENTS AND METHODS

Patient Population
Between 1988 and 2006, 691 patients were treated at the University of Chicago Pritzker School of Medicine with curative-intent RT for nonmetastatic prostate adenocarcinoma. All men had known medication use at initial consultation. Patients were treated with external-beam RT and/or brachytherapy seed implants; patients with prior prostatectomy were excluded. The median age was 69 years. The majority of patients had clinical stage T1-2a disease (81%) and a median Gleason score (GS) of 6, with a median PSA of 8. 4 . A median of eight biopsy cores were taken with a median of three positive cores. Only seven patients (1%) had radiographic or pathologic lymph nodepositive disease. Patients were stratified as low risk (T1-2a, PSA Յ 10, GS Յ 6), intermediate risk (either T2b and PSA 10-20 or GS 7), or high risk (Ն T2c and PSA Ͼ 20 or GS 8-10), based on National Comprehensive Cancer Network criteria. 30 Medication use was documented in all patients at initial visit and each follow-up. One hundred eighty-nine patients (27%) received statin therapy during RT (n ϭ 150) or during follow-up (n ϭ 39).
Data Collection
Physicians at the University of Chicago reviewed available medical records with approval from the institutional review board. Patients were clinically staged according to the American Joint Commission on Cancer staging system. Typical work-up included a digital rectal examination, PSA, and transrectal ultrasound with biopsies. Clinical stage was defined strictly on digital rectal exam only. Patients underwent computed tomography-based imaging or bone scans as indicated, based on risk factors. Information was collected regarding baseline demographic, disease, and treatment characteristics.
For the group of patients receiving statin therapy, a physician recorded information on the type of statin used and statin dose. The patient population used six different types of statins: atorvastatin, lovastatin, fluvastatin, pravastatin, simvastatin, and rosuvastatin. Statin doses were adjusted by normalizing to simvastatin equivalents. 24 
Treatment
All patients were treated with curative-intent RT consisting of externalbeam RT in 584 men (84%), brachytherapy seed implants in 61 men (9%), or a combination of both in 46 men (7%). Ninety-three percent of patients received RT to the prostate and seminal vesicles only. Patients treated with external-beam RT received treatment once daily, 5 d/wk. Forty-one percent were treated using intensity-modulated RT. 32 The median radiation dose was 72 Gy with a median treatment time of 51 days. Patients treated with brachytherapy seed implants alone received 144 Gy. Two hundred eighty-six patients (41%) received androgen deprivation therapy (ADT) in the neoadjuvant, concurrent, or adjuvant setting with RT, consisting of a gonadotropinreleasing hormone with or without a concurrent antiandrogen. The median duration of ADT was 4 months. Of 258 patients with records of ADT duration available, 226 (87%) received Յ 6 months of ADT.
Assessment of Response
The primary end point was freedom from biochemical failure (FFBF) defined using the Phoenix definition (PSA nadir ϩ 2 ng/mL). Other end points included RFS, which was inclusive of biochemical failure; distant metastasis; salvage ADT; death from any cause; freedom from androgen deprivation therapy; freedom from distant metastases; cause-specific (death from prostate cancer) survival; and overall survival. With all end points except RFS, men who did not meet the specified end point of interest (eg, FFBF) but had any other event (eg, death) were censored at the time of last follow-up pertaining to that end point. The median follow-up time was 50 months from the completion of RT to the last measured PSA.
Statistics
Differences in categoric variables between groups were tested using 2 analysis. Continuous variables were compared using two-sample t tests. Kaplan-Meier curves for FFBF were generated, and survival comparisons were made with the log-rank test. Univariate analysis was performed according to risk category, radiation dose, use of statins, use of ADT, and lipid levels. Multivariable analysis was performed using a Cox proportional hazards model 33 to determine prognostic factors for FFBF and RFS. The effects of statin use and other covariates in terms of the cumulative incidence function, treating deaths from causes other than prostate cancer as a competing risk, were estimated using the methods described in Fine and Gray.
34 Explanatory variables were included in the multivariable model if they were found to be associated with outcome (P Ͻ .1) on univariate analysis.
RESULTS
Overall Group
Analysis of the entire cohort (N ϭ 691) revealed an FFBF of 83% and an RFS of 73% at 4 years. By risk category, 4-year FFBF was 92% for low-risk patients, 87% for intermediate-risk patients, and 67% for high-risk patients (P Ͻ .001). Four-year RFS was 83% for low-risk patients, 77% for intermediate-risk patients, and 56% for high-risk patients (P Ͻ .001).
The group of patients taking statins had more favorable pretreatment characteristics (Table 1 ). Patients taking statins had significantly lower median pretreatment PSA (7.2 v 8.7 ng/mL; P ϭ .0166) and more T1-2a disease (88% v 79%; P ϭ .0208). Higher percentages in the statin group were treated with intensity-modulated RT (59% v 34%; P Ͻ .001) and ADT (47% v 39%; P ϭ .0913). Median radiation dose was higher in the statin group (74 v 72 Gy; P ϭ .0231).
Factors associated with improved FFBF on univariate analysis included statin use (P Ͻ .001), risk group (P Ͻ .001), total cholesterol Ͻ 187 (P ϭ .0494), and LDL Ͻ 110 (P ϭ .0462; Table 2 ). Statin use (P Ͻ .001) and risk group (P Ͻ .001) were also associated with improved RFS. On multivariable analysis, factors associated with improved FFBF were statin use (P ϭ .002) and log PSA (P Ͻ .001; Table  3 ). Factors associated with RFS on multivariable analysis included log PSA (P Ͻ .001), dose Ͼ 74 Gy or brachytherapy (P Ͻ .001), statin use (P ϭ .005), and GS Ͻ 7 (P ϭ .04). There was a trend toward improved RFS with use of hormone therapy (P ϭ .06).
Analysis of Patients Receiving Statins
A total of 189 patients (27%) received statin therapy during or after RT. Statin users had significantly better FFBF (P Ͻ .001; Fig 1) , RFS (P Ͻ .001; Fig 2) , and freedom from androgen deprivation therapy (98% v 93% at 4 years; P ϭ .0011). Statin use was associated with improved FFBF in low-risk (95% v 91%; P ϭ .0401), intermediate-risk (94% v 84%; P ϭ .0331), and high-risk groups (85% v 61%; P ϭ .0034). There was no difference in overall survival (94% v 90%; P ϭ .1235), cause-specific survival (99% v 97%; P ϭ .1535), and freedom from distant metastases (98% v 96%; To address the possibility that competing risks of mortality could influence the results, cumulative incidence analysis was performed for FFBF and RFS, treating death from other causes as a competing risk. The results for biochemical failure are displayed in Appendix Figure  A1 (online only). Fine and Gray's test indicated a favorable impact of statin use on biochemical failure (P Ͻ .001). The effect of statin use on death from other causes was not statistically significant (P ϭ .1999). Similarly, statin use favorably impacted RFS (P Ͻ .001), but not death from other causes (P ϭ .1747; data not shown). In a multivariable model that included competing risks of mortality (Appendix Table  A1 , online only), statin use remained significantly associated with improved FFBF (P ϭ .03) and RFS (P ϭ .007).
Patients benefited from statin therapy independent of treatment characteristics such as ADT use or radiation dose. In the subset of patients treated with ADT, FFBF was 93% for statin users compared with 77% for nonusers (P ϭ .0040). In the subset not receiving ADT, a significant benefit was also seen (93% v 82%; P ϭ .0011). The effect of statin therapy was seen regardless of radiation dose, but a larger benefit was seen in men treated with lower radiation doses. In men treated with Ͻ 74 Gy, FFBF was 93% for statin users compared with 75% for nonusers (P ϭ .0025). In those treated with Ͼ 74 Gy or seed implants, FFBF was 92% in statin users and 85% in nonusers (P ϭ .0167).
The type of statin used was known for all 189 patients, and there was no relationship between the type of statin and FFBF by log-rank analysis (P ϭ .1190). This analysis was limited by patient numbers because the majority of patients were taking either atorvastatin (n ϭ 96) or simvastatin (n ϭ 49). There was no significant difference in FFBF (P ϭ .9375) or RFS (P ϭ .5367) for statin dose Ͻ 40 mg compared with Ͼ 40 mg simvastatin equivalents.
Lipid panel data were collected when available, including values for total cholesterol, LDL, high-density lipoprotein, and triglycerides. All men with missing data were excluded from this analysis. There was no correlation between pretreatment high-density lipoprotein and triglycerides and any outcomes. There was, however, an association between lower total cholesterol and LDL pretreatment values with improved FFBF. Patients were stratified on the basis of whether their pretreatment total cholesterol and LDL values were lower or higher than the median value (187 and 110, respectively). Those with lower total cholesterol, stratified by the median, had improved FFBF at 4 years (89% v 80%; P ϭ .0494). Lower LDL was also associated with improved FFBF (96% v 85%; P ϭ .0462). Of note, there were no significant differences in pretreatment PSA, T-stage, or GS distributions between the low-and high-cholesterol groups or between the low-and high-LDL groups. The prognostic effect of LDL level was greatest in men not treated with concurrent ADT, with improved FFBF for men with LDL Ͻ 110 (100% v 88%; P ϭ .0119). Patients were divided into four groups depending on statin use and LDL level: (1) statin, LDL greater than or equal to the median; (2) statin, LDL less than the median; (3) no statin, LDL greater than or equal to the median; and (4) no statin, LDL less than the median. Men taking a statin with LDL less than median had the highest FFBF, while men not taking a statin with LDL greater than or equal to the median had the lowest FFBF (98% v 78%; P ϭ .0918). In the subset of men with LDL information available and not taking statins, LDL was associated with FFBF at 4 years, although this difference was not statistically significant (96% LDL less than median v 78% LDL greater than or equal to median; P ϭ .1552). A separate multivariable analysis including only statin use and LDL in the model was performed against FFBF. In this analysis, lower LDL was associated with improved FFBF (P ϭ .0473), while statin use was not (P ϭ .1394; Table 4 ).
DISCUSSION
Statin use has steadily increased over the past two decades, and it is estimated that 24 million Americans are using these medications. [35] [36] [37] Given the favorable effect of statins on vascular health, 17 statin use is expected to increase worldwide. The potential role of statins in carcinogenesis and cancer therapy has been investigated in several studies, with many positive results. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] This study was conducted to determine whether statin use is associated with improved outcomes in patients treated with RT for prostate cancer.
Our study showed that statin use improved FFBF and RFS in prostate cancer patients treated with RT. This effect was seen across all risk categories and RT dose ranges and was independent of ADT use. There was an association between lower LDL levels and improved FFBF. Because statin use lowers LDL levels, it is difficult to determine whether improved outcomes are truly related to lower LDL or whether low LDL and improved FFBF are both by-products of statin use. Interestingly, low LDL was more predictive of improved FFBF in men not receiving ADT (P ϭ .0306) than in men receiving ADT (P ϭ .7920). This finding raises the question of whether LDL may represent the activity of, or interact with, the hormonal axis in lieu of more traditional forms of hormonal therapy. Cholesterol is a precursor for androgen formation, and it is conceivable that by lowering cholesterol levels, statins may lower levels of intraprostatic androgens. 38 Hamilton et al 38 postulated that depletion of intraprostatic androgens could, in turn, result in PSA decline. In our study, statin use was associated with lower PSA and clinical stage at diagnosis. Additionally, LDL levels may be modifying intraprostatic hormonal levels, resulting in a differential effect of RT.
Statins inhibit 3-hydroxy-3-methyl-glutaryl coenzyme A (HMGCoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, to lower LDL cholesterol and triglyceride levels. 39 Multiple studies have shown that lipogenic enzymes contribute to cancer pathogenesis 40, 41 and that increased cholesterol content in prostatic tissue correlates with malignancy. [42] [43] [44] [45] The relationship between statins and carcinogenesis is undefined, but there are several possible explanations. Reducing cholesterol bioavailability inhibits the prosurvival effects of epidermal growth factor receptor activation. 45, 46 Cholesterol disruption has been shown to inhibit AKT1 activity and stimulate apoptosis in prostate cells. [44] [45] [46] While the effects of statins on prostate biology may be mediated by cholesterol, it is also possible that statins have non-cholesterol-mediated effects. For instance, statin use results in depletion of mevalonate. Mevalonate is a precursor of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, both of which are important for function of intracellular survival signals such as Rho and Ras. 46, 47 Clinical data regarding the use of statin therapy in the setting of prostate cancer treatment are limited. Another study of 871 men, 48 presented in abstract form, indicated an improvement in PSA RFS for men taking statins treated with RT. However, in a similar analysis of 968 men, Soto et al 49 found that statin use was associated with PFS on univariate but not on multivariable analysis. The statin users tended to have better disease characteristics such as lower pretreatment PSA and T stage, leading to fewer high-risk patients taking statins. As a result, the beneficial effect of statins may have been confounded with less advanced tumors at presentation. Differences in patient population, RT techniques, or follow-up time may have contributed to the discrepancy in results among these studies. It is possible that patients undergoing more aggressive radiation treatments derive less benefit from statin use. In contrast to the study by Soto et al, patients in our study were treated with lower radiation doses and less frequently received whole pelvis RT. Similarly, Moyad et al 50 did not report a benefit to statin use in patients treated with brachytherapy, which could be related to the relatively high radiation doses delivered with brachytherapy.
Conclusions from this data set are limited by the retrospective nature of analysis. The study cohort is heterogeneous, without control over RT techniques or duration of statin therapy, dose, or timing over the period of follow-up. Subset and multivariable analyses attempted to control for this heterogeneity, and the results indicate that the benefit seen for men taking a statin is not only the result of differences in stage or grade at presentation. However, residual confounding or confounding due to other factors not controlled for cannot be ruled out, and a randomized study would be necessary to test this hypothesis. Our study suggests an association between lower LDL levels and improved FFBF, but numbers are relatively limited in this subset, and this association should be explored in future studies. Finally, although the median follow-up is sufficient to analyze end points including FFBF and RFS, the follow-up needs to mature further to draw conclusions regarding end points such as cause-specific or overall mortality.
Despite the limitations, the implications of this study are important. Statins have been shown to have in vitro anticancer activity 51, 52 and synergistic effects with radiation in various cell lines, by means of cell cycle arrest and apoptosis.
47,51,53-55 Our own preliminary preclinical experiments in prostate cancer xenografts demonstrates a clear radiosensitizing effect of simvastatin on cell growth (unpublished data). If confirmed as potent radiation sensitizers or if they have anticancer effects otherwise, statins could allow for less use of ADT as well as radiation dose de-escalation. These modifications could in turn lead to decreased treatment costs and decreased treatment morbidities. [56] [57] [58] Further study is essential, especially regarding the mechanism of action, to explore the possibility that statin therapy may improve clinical outcomes, treatment costs, and treatment morbidity in men treated with RT for prostate cancer. In number of citaƟons, JCO ranks second among 141 oncology journals and ranks 25th among all 6,598 scienƟfic journals surveyed. JCO arƟcles were cited more than 97,000 Ɵmes in 2008-a 20% increase over the previous year.
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